156 related articles for article (PubMed ID: 32339447)
1. hIL-7-hyFc, A Long-Acting IL-7, Increased Absolute Lymphocyte Count in Healthy Subjects.
Lee SW; Choi D; Heo M; Shin EC; Park SH; Kim SJ; Oh YK; Lee BH; Yang SH; Sung YC; Lee H
Clin Transl Sci; 2020 Nov; 13(6):1161-1169. PubMed ID: 32339447
[TBL] [Abstract][Full Text] [Related]
2. rhIL-7-hyFc and hIL-2/TCB2c combination promotes an immune-stimulatory tumor microenvironment that improves antitumor efficacy of checkpoint inhibitors.
Lee M; Im SK; Baek S; Ji M; Kim M; Lee EJ; Ji ST; Ferrando-Martinez S; Wolfarth A; Lee JY; Kim D; Choi D
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38471713
[TBL] [Abstract][Full Text] [Related]
3. A single administration of hIL-7-hyFc induces long-lasting T-cell expansion with maintained effector functions.
Kim S; Lee SW; Koh JY; Choi D; Heo M; Chung JY; Lee BH; Yang SH; Sung YC; Lee H; Shin EC; Park SH
Blood Adv; 2022 Dec; 6(23):6093-6107. PubMed ID: 36206199
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial.
Francois B; Jeannet R; Daix T; Walton AH; Shotwell MS; Unsinger J; Monneret G; Rimmelé T; Blood T; Morre M; Gregoire A; Mayo GA; Blood J; Durum SK; Sherwood ER; Hotchkiss RS
JCI Insight; 2018 Mar; 3(5):. PubMed ID: 29515037
[TBL] [Abstract][Full Text] [Related]
5. Compassionate use of recombinant human IL-7-hyFc as a salvage treatment for restoring lymphopenia in patients with recurrent glioblastoma.
Ahn S; Park JS; Kim H; Heo M; Sung YC; Jeun SS
Cancer Med; 2023 Mar; 12(6):6778-6787. PubMed ID: 36583472
[TBL] [Abstract][Full Text] [Related]
6. Natural form of noncytolytic flexible human Fc as a long-acting carrier of agonistic ligand, erythropoietin.
Im SJ; Yang SI; Yang SH; Choi DH; Choi SY; Kim HS; Jang DS; Jin KS; Chung YK; Kim SH; Paik SH; Park YC; Chung MK; Kim YB; Han KH; Choi KY; Sung YC
PLoS One; 2011; 6(9):e24574. PubMed ID: 21957455
[TBL] [Abstract][Full Text] [Related]
7. A Double-Blind, Phase I, Single Ascending Dose Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of BOS161721 in Healthy Subjects.
Hussaini A; Mukherjee R; Berdieva DM; Glogowski C; Mountfield R; Ho PTC
Clin Transl Sci; 2020 Mar; 13(2):337-344. PubMed ID: 31664766
[TBL] [Abstract][Full Text] [Related]
8. Repeated Cycles of Recombinant Human Interleukin 7 in HIV-Infected Patients With Low CD4 T-Cell Reconstitution on Antiretroviral Therapy: Results of 2 Phase II Multicenter Studies.
Thiébaut R; Jarne A; Routy JP; Sereti I; Fischl M; Ive P; Speck RF; D'Offizi G; Casari S; Commenges D; Foulkes S; Natarajan V; Croughs T; Delfraissy JF; Tambussi G; Levy Y; Lederman MM
Clin Infect Dis; 2016 May; 62(9):1178-1185. PubMed ID: 26908786
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects.
Tang KY; Lickliter J; Huang ZH; Xian ZS; Chen HY; Huang C; Xiao C; Wang YP; Tan Y; Xu LF; Huang YL; Yan XQ
Cell Mol Immunol; 2019 May; 16(5):473-482. PubMed ID: 29670279
[TBL] [Abstract][Full Text] [Related]
10. Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study.
Beigel JH; Voell J; Kumar P; Raviprakash K; Wu H; Jiao JA; Sullivan E; Luke T; Davey RT
Lancet Infect Dis; 2018 Apr; 18(4):410-418. PubMed ID: 29329957
[TBL] [Abstract][Full Text] [Related]
11. The pharmacology study of a new recombinant TNF receptor-hyFc fusion protein.
Lee JH; Cho JH; Yeo J; Lee SH; Yang SH; Sung YC; Kang JH; Park CS
Biologicals; 2013 Mar; 41(2):77-83. PubMed ID: 23190454
[TBL] [Abstract][Full Text] [Related]
12. Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Markowitz M; Frank I; Grant RM; Mayer KH; Elion R; Goldstein D; Fisher C; Sobieszczyk ME; Gallant JE; Van Tieu H; Weinberg W; Margolis DA; Hudson KJ; Stancil BS; Ford SL; Patel P; Gould E; Rinehart AR; Smith KY; Spreen WR
Lancet HIV; 2017 Aug; 4(8):e331-e340. PubMed ID: 28546090
[TBL] [Abstract][Full Text] [Related]
13. Tolerability and pharmacokinetics of TB-402 in healthy male volunteers.
Verhamme P; Pakola S; Jensen TJ; Berggren K; Sonesson E; Saint-Remy JM; Balchen T; Belmans A; Cahillane G; Stassen JM; Peerlinck K; Glazer S; Jacquemin M
Clin Ther; 2010 Jun; 32(6):1205-20. PubMed ID: 20637972
[TBL] [Abstract][Full Text] [Related]
14. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial.
Penn-Nicholson A; Tameris M; Smit E; Day TA; Musvosvi M; Jayashankar L; Vergara J; Mabwe S; Bilek N; Geldenhuys H; Luabeya AK; Ellis R; Ginsberg AM; Hanekom WA; Reed SG; Coler RN; Scriba TJ; Hatherill M;
Lancet Respir Med; 2018 Apr; 6(4):287-298. PubMed ID: 29595510
[TBL] [Abstract][Full Text] [Related]
15. Understanding the pharmacokinetic journey of Fc-fusion protein, rhIL-7-hyFc using complementary approach of two analytical methods, accelerator mass spectrometry and ELISA.
Kim A; Oh MS; Lee GH; Song S; Byun MS; Choi D; Yu BY; Lee H
Antib Ther; 2024 Apr; 7(2):105-113. PubMed ID: 38566969
[TBL] [Abstract][Full Text] [Related]
16. Hybrid Fc-fused interleukin-7 induces an inflamed tumor microenvironment and improves the efficacy of cancer immunotherapy.
Kim JH; Kim YM; Choi D; Jo SB; Park HW; Hong SW; Park S; Kim S; Moon S; You G; Kang YW; Park Y; Lee BH; Lee SW
Clin Transl Immunology; 2020; 9(9):e1168. PubMed ID: 32994996
[TBL] [Abstract][Full Text] [Related]
17. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study.
Tak PP; Thurlings RM; Rossier C; Nestorov I; Dimic A; Mircetic V; Rischmueller M; Nasonov E; Shmidt E; Emery P; Munafo A
Arthritis Rheum; 2008 Jan; 58(1):61-72. PubMed ID: 18163485
[TBL] [Abstract][Full Text] [Related]
18. A long-acting erythropoietin fused with noncytolytic human Fc for the treatment of anemia.
Yang SH; Yang SI; Chung YK
Arch Pharm Res; 2012 May; 35(5):757-9. PubMed ID: 22644842
[TBL] [Abstract][Full Text] [Related]
19. Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.
Ellis J; van Maurik A; Fortunato L; Gisbert S; Chen K; Schwartz A; McHugh S; Want A; Santos Franco S; Oliveira JJ; Price J; Coles A; Brown K; Su D; Craigen JL; Yang J; Brett S; Davis B; Cheriyan J; Kousin-Ezewu O; Gray F; Thompson PW; Fernando D
Br J Clin Pharmacol; 2019 Feb; 85(2):304-315. PubMed ID: 30161291
[TBL] [Abstract][Full Text] [Related]
20. A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers.
Staton TL; Peng K; Owen R; Choy DF; Cabanski CR; Fong A; Brunstein F; Alatsis KR; Chen H
BMC Pulm Med; 2019 Jan; 19(1):5. PubMed ID: 30616547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
